Zacks Research Issues Pessimistic Forecast for AXSM Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Zacks Research reduced their FY2024 EPS estimates for shares of Axsome Therapeutics in a research note issued on Tuesday, January 7th. Zacks Research analyst R. Department now expects that the company will earn ($5.42) per share for the year, down from their previous forecast of ($5.32). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.60) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($1.71) EPS, Q2 2025 earnings at ($1.60) EPS, Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.77) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at ($0.67) EPS.

Several other research firms have also recently issued reports on AXSM. Robert W. Baird raised their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Mizuho dropped their price target on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, December 31st. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 target price on shares of Axsome Therapeutics in a research report on Monday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $121.00 price target on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $127.29.

Axsome Therapeutics Stock Down 1.4 %

Shares of AXSM opened at $82.57 on Thursday. The business’s fifty day moving average price is $92.62 and its two-hundred day moving average price is $89.09. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -12.64 and a beta of 1.04. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $105.00. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the prior year, the firm earned ($1.32) earnings per share.

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sofinnova Investments Inc. bought a new stake in Axsome Therapeutics in the 2nd quarter valued at approximately $24,971,000. Iron Triangle Partners LP bought a new stake in shares of Axsome Therapeutics in the third quarter worth $22,671,000. Tri Locum Partners LP boosted its holdings in Axsome Therapeutics by 198.4% during the second quarter. Tri Locum Partners LP now owns 306,513 shares of the company’s stock worth $24,674,000 after purchasing an additional 203,802 shares during the last quarter. FMR LLC grew its position in Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after purchasing an additional 185,951 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in Axsome Therapeutics by 47.5% in the 3rd quarter. Franklin Resources Inc. now owns 160,534 shares of the company’s stock valued at $13,713,000 after buying an additional 51,696 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.